Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708027 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL17337592 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL21708028 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL17337593 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL18289855 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL25721685 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL14962705 | 1.00 | CYP2D6 (0.33) | CYP2D6DPP4 | |
| SCHEMBL18923780 | 0.91 | — | — | |
| SCHEMBL31032956 | 0.91 | DPP4 (0.38) | CYP2D6DPP4 | |
| SCHEMBL21117488 | 0.90 | CYP2D6 (0.32) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598770-A | Salt for synthesizing intermediate of monomethyl auristatin E, and preparation method and application thereof | 无锡药明合联生物技术有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-113416229-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2024-11-26 | — | — | US | disclosed |
| CN-118598770-A | Salt for synthesizing intermediate of monomethyl auristatin E, and preparation method and application thereof | 无锡药明合联生物技术有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118598770-A | Salt for synthesizing intermediate of monomethyl auristatin E, and preparation method and application thereof | 无锡药明合联生物技术有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2023-05-30 | — | — | US | disclosed |
| US-20230071763-A1 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-8288352-B2 | Auristatins having an aminobenzoic acid unit at the N terminus | SEATTLE GENETICS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288352-B2 | Auristatins having an aminobenzoic acid unit at the N terminus | SEATTLE GENETICS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011154359-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154359-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071763-A1 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | AURKC, AURKA, AURKB | CYP2D6 4787/4885DPP4 3207/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | CYP2D6 990/4885DPP4 1204/4885 |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CYP2D6 3275/4885DPP4 2986/4885 |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | CYP2D6 3056/4885DPP4 1664/4885 |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | AURKB, AURKA, AURKC | CYP2D6 4336/4885DPP4 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.